Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synapse Biomedical gets warning letter for IDE studies

This article was originally published in The Gray Sheet

Executive Summary

Firm is cited in a June 20 FDA 1warning letter for failing to perform some sponsor obligations in pivotal and pilot investigational device studies. The letter comes on the heels of Synapse's June 17 FDA approval for its NeuRx DPS diaphragm pacing system for certain spinal cord injury patients via humanitarian device exemption (HDE). NeuRx DPS stimulates the diaphragm and allows patients to breathe for at least four hours a day without a mechanical ventilator. According to the letter, based on an inspection conducted Feb. 25-March 18, Synapse expanded one study to four additional clinical sites without prior FDA approval. The firm also failed to adequately monitor the studies and obtain signed agreements from each investigator with full financial disclosure information. Synapse also shipped replacement parts for the device directly to trial subjects. CEO Anthony Ignagni says the issues are not related to product quality or performance and do not preclude the firm from shipping its products for use in spinal cord injury patients or in clinical trials of patients with amyotrophic lateral sclerosis (2"The Gray Sheet" June 23, 2008, p. 21)
Advertisement

Related Content

Synapse Biomedical Debuts Diaphragm Pacer, HDE-Cleared To Aid Breathing
Synapse Biomedical Debuts Diaphragm Pacer, HDE-Cleared To Aid Breathing
Advertisement
UsernamePublicRestriction

Register

MT026337

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel